innerbuddies gut microbiome testing

Gut Microbiome & Prediabetes: How Impaired Glucose Tolerance Starts and Improves

Impaired glucose tolerance (prediabetes) isn’t just a pancreas story—it’s also a gut story. The trillions of microbes in your intestines help shape how efficiently you digest carbohydrates, how strongly your gut barrier protects you from inflammatory signals, and how your body responds to insulin after meals. When the gut microbiome shifts out of balance, it can contribute to slower glucose clearance, greater inflammation, and reduced insulin sensitivity—key steps in the path from “normal” blood sugar to prediabetes.

Research increasingly suggests that the gut ecosystem influences glucose regulation through several interconnected mechanisms: changes in microbial diversity, altered production of short-chain fatty acids (like butyrate), and shifts in bile acid metabolism. Some microbial patterns are associated with higher levels of metabolic inflammation and increased gut permeability, which can make it easier for inflammatory molecules to reach the bloodstream and interfere with insulin signaling. Meanwhile, less favorable carbohydrate fermentation can reduce beneficial metabolites that normally support metabolic health.

The good news: improving impaired glucose tolerance often goes hand in hand with supporting a healthier microbiome. Diet quality—especially adequate fiber from diverse plant sources—can help restore beneficial fermentation patterns, increase short-chain fatty acid production, and strengthen gut barrier function. Targeted lifestyle steps (such as regular physical activity and sleep consistency) further support microbial balance, which may help your body process glucose more effectively. If you’re looking to “get back on track,” the gut microbiome can be a powerful—and practical—place to start.

Take a Gut Microbiome Test for Impaired Glucose Tolerance Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Impaired glucose tolerance

Impaired glucose tolerance (IGT) is an early, often reversible stage on the path to type 2 diabetes, and gut microbiome dynamics help set the pace of glucose regulation. The gut ecosystem influences insulin sensitivity through inflammation, gut barrier integrity, bile acid metabolism, and microbial metabolites such as short-chain fatty acids (SCFAs) like butyrate. When diversity falls and SCFA production wanes—often from low fiber intake and high ultra-processed food consumption—the body may shift toward a more glycemic, insulin-resistant state with post-meal glucose elevations and related symptoms.

Microbial patterns in IGT typically feature reduced diversity and diminished SCFA-producing capacity, along with shifts in bile acid signaling via FXR and TGR5 and a tendency toward low-grade inflammation. These changes can worsen glucose control and insulin signaling, especially after meals. Population estimates show roughly a quarter of adults have some form of prediabetes, with IGT accounting for a sizable share depending on diagnostic criteria. Testing can reveal these patterns, help explain symptoms like post-prandial fatigue or cravings, and guide targeted dietary and lifestyle changes to boost SCFA production and gut barrier function.

Interventions emphasize fermentable, soluble fiber, minimally processed foods, and regular physical activity to support beneficial microbes and incretin signaling (GLP-1). When appropriate, clinician-guided probiotics or postbiotics may be used to strengthen gut barrier and reduce inflammation, improving glucose outcomes. Programs like InnerBuddies leverage microbiome testing to personalize recommendations, focusing on higher prebiotic fiber, reduced ultra-processed foods, and ongoing monitoring of glucose responses to translate microbiome science into practical prevention of progression from IGT toward type 2 diabetes.

  • Loss of butyrate-producing taxa (Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Anaerostipes spp.) in IGT reduces SCFA production, impairing insulin sensitivity and hepatic glucose regulation.
  • Akkermansia muciniphila, a mucin-degrading barrier defender, is often reduced in IGT; boosting its abundance may strengthen gut barrier and improve postprandial glucose control.
  • Bifidobacterium spp. support fiber fermentation and incretin signaling, promoting SCFA production and GLP-1–mediated insulin responses that help stabilize postprandial glucose.
  • Expansion of pro-inflammatory taxa—Enterobacteriaceae (E. coli/Shigella), Bilophila wadsworthia, Ruminococcus gnavus group, Bacteroides fragilis group, and Fusobacterium nucleatum group—can drive endotoxemia and insulin resistance in IGT.
  • Lower abundance of Christensenellaceae is associated with dysglycemia; maintaining or boosting this group aligns with healthier metabolic profiles and leanness.
Take a Gut Microbiome Test for Impaired Glucose Tolerance Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Prediabetes

Impaired glucose tolerance (IGT), often considered a key stage on the path to type 2 diabetes, is closely linked to how efficiently the body regulates blood sugar. While insulin resistance is a central driver, the gut microbiome can influence this process by shaping inflammation, bile acid metabolism, and the production of beneficial microbial metabolites—especially short-chain fatty acids (SCFAs) like butyrate. When the gut ecosystem shifts (often toward lower diversity and less SCFA-producing activity), it can promote a higher-glycemic environment through increased gut permeability (“leaky gut”), altered signaling to metabolic organs, and impaired regulation of glucose uptake.

Research increasingly suggests that the gut microbiome contributes to the earliest metabolic changes by affecting energy harvest and host metabolism, modulating immune responses, and influencing incretin hormones (e.g., GLP-1) that help coordinate insulin release and appetite regulation. Certain microbial profiles are associated with improved insulin sensitivity, while others correlate with worsening glucose tolerance. In prediabetes and IGT, dysbiosis may also disrupt bile acid composition; since bile acids act as signaling molecules via receptors like FXR and TGR5, changes in microbial conversion can affect insulin sensitivity and glucose homeostasis. Lifestyle and diet—particularly high intakes of ultra-processed foods and low fiber intake—can further reinforce these microbial shifts.

The good news is that gut-driven mechanisms are modifiable. Diets that increase fermentable fiber (prebiotic foods and soluble fibers), emphasize minimally processed whole foods, and support SCFA production have been shown to improve insulin sensitivity in many people. Regular physical activity also benefits the microbiome and metabolic signaling. Targeted strategies—such as specific prebiotic fibers, a microbiome-supportive dietary pattern, and in some cases clinician-guided probiotics or postbiotics—may help strengthen gut barrier function, reduce inflammatory tone, and improve glucose regulation. Because responses vary by baseline microbiome and metabolic health, the most effective plan typically combines dietary fiber quality, consistent lifestyle habits, and individualized monitoring of glucose outcomes.

  • Increased blood sugar levels after meals (postprandial hyperglycemia)
  • Prediabetes-range A1C or fasting glucose results
  • Fatigue and low energy, especially after eating
  • Increased thirst and frequent urination (mild or intermittent)
  • Unexplained weight gain or difficulty losing weight
  • Increased hunger/cravings, particularly for carbohydrates or sweets
  • Blurred vision or changes in vision (often intermittent)
  • Slow wound healing or frequent infections
Take a Gut Microbiome Test for Impaired Glucose Tolerance Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Impaired glucose tolerance

This information is relevant for people with impaired glucose tolerance (IGT) or early prediabetes—especially those who have post-meal (postprandial) blood sugar spikes, borderline A1C or fasting glucose results, or early metabolic symptoms that suggest the body is struggling to regulate glucose. It’s also relevant for individuals who notice energy crashes after eating, increased hunger/cravings (often for carbs or sweets), or subtle signs such as mild, intermittent increased thirst and more frequent urination.

It may be particularly useful for those who have difficulty losing weight or have unexplained weight gain alongside fluctuating blood sugar, since gut microbiome changes can influence inflammation, appetite-related hormone signaling, and glucose uptake. It’s also a good fit for people experiencing blurred or changing vision, slow wound healing, or recurrent infections—symptoms that can occur when glucose control is intermittently elevated. If you’re concerned that your dietary pattern (e.g., low fiber, highly processed foods) could be contributing to dysbiosis, this gut-focused approach may align with your goals.

This is also relevant for anyone looking for modifiable, diet-and-lifestyle-driven strategies to support metabolic health, rather than focusing only on numbers like A1C. Because gut microbes can affect short-chain fatty acid (SCFA) production (notably butyrate), gut barrier integrity (“leaky gut”), and bile acid signaling pathways (FXR/TGR5) that influence insulin sensitivity, it may help to those interested in improving glucose regulation through higher-fiber, minimally processed foods, fermented or prebiotic intake, and—when appropriate—clinician-guided probiotics or postbiotics.

Impaired glucose tolerance (IGT)—a common prediabetes stage and an early warning signal on the path to type 2 diabetes—is extremely prevalent worldwide. Epidemiologic studies estimate that roughly 1 in 4 adults (about 25%) have some form of prediabetes, and IGT accounts for a substantial portion of these cases, commonly reported around ~10%–15% of adults depending on the population and diagnostic criteria used (e.g., whether testing is based on fasting glucose vs. 2‑hour oral glucose tolerance testing).

Because IGT is often driven by metabolic dysfunction (including insulin resistance) and can be influenced by gut microbiome–related factors (like inflammation, gut barrier integrity, and reduced SCFA-producing activity), many people never recognize it early. Symptoms—when present—often cluster around post-meal blood sugar elevations (postprandial hyperglycemia), borderline A1C or fasting glucose results, fatigue after eating, increased thirst/frequent urination, and sometimes weight gain or cravings. Clinically, this helps explain why a large share of adults with prediabetes/IGT remain undiagnosed until routine screening reveals abnormal glucose markers.

Prevalence is also strongly influenced by age, adiposity, diet quality (especially low fiber/low fermentable carbohydrates and higher ultra-processed intake), physical inactivity, and family history. In many real-world cohorts, a meaningful fraction of those with IGT progress to type 2 diabetes over time—supporting why improving gut–metabolic pathways is considered a key prevention target. Overall, the high prevalence of prediabetes (often ~25% of adults) and the typical “subclinical” nature of IGT symptoms make it one of the most common metabolic conditions, affecting tens of millions of people in many countries.

Take a Gut Microbiome Test for Impaired Glucose Tolerance Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome & Prediabetes: How Impaired Glucose Tolerance Starts and Can Be Improved

Impaired glucose tolerance (IGT) represents an early, often reversible stage on the path to type 2 diabetes, and the gut microbiome appears to play a meaningful role in how efficiently the body regulates blood sugar. Gut microbes influence glucose control through multiple interconnected pathways, including shaping low-grade inflammation, affecting gut barrier integrity (so-called “leaky gut”), and producing metabolites—especially short-chain fatty acids (SCFAs) like butyrate—that help improve insulin sensitivity. When the microbiome shifts toward lower diversity and reduced SCFA-producing capacity (often worsened by low fiber intake and higher consumption of ultra-processed foods), the body can develop a more glycemic, insulin-resistant environment—consistent with post-meal blood sugar elevations and other early metabolic symptoms.

Microbial communities also interact with bile acid metabolism, which can affect glucose homeostasis through signaling receptors such as FXR and TGR5. Because gut bacteria convert primary bile acids into more metabolically active secondary forms, dysbiosis may alter the bile acid “signal” that coordinates insulin sensitivity and energy balance. This gut–bile acid–metabolic axis helps explain why some people with prediabetes-range A1C or fasting glucose show persistent difficulties with glucose regulation, even when insulin resistance is not yet fully established.

Finally, the gut microbiome can modulate metabolic hormones (including incretins like GLP-1) that regulate insulin release, appetite, and postprandial glucose levels. Changes in microbial metabolite production and immune signaling can disrupt these pathways, contributing to symptoms such as fatigue after eating, carbohydrate or sugar cravings, and intermittent blurred vision associated with glucose swings. The encouraging takeaway is that these microbiome-driven mechanisms are modifiable: increasing fermentable and soluble fiber (prebiotics), emphasizing minimally processed whole foods, and supporting SCFA production can strengthen gut barrier function, lower inflammatory tone, and improve glucose outcomes for many individuals.

Take a Gut Microbiome Test for Impaired Glucose Tolerance Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Impaired glucose tolerance

  • Altered SCFA production (e.g., butyrate, propionate) that normally improves insulin sensitivity and helps regulate hepatic glucose output
  • Low-grade immune activation/inflammation driven by dysbiosis, which can impair insulin signaling (systemic insulin resistance even at the IGT stage)
  • Gut barrier dysfunction (“leaky gut”) enabling endotoxin/LPS translocation, further amplifying inflammation and worsening glucose regulation
  • Changes in bile acid metabolism via microbial conversion of primary to secondary bile acids, modulating FXR/TGR5 signaling that influences glucose homeostasis and insulin sensitivity
  • Reduced microbial diversity and fewer beneficial fermenters (often linked to low fiber and higher ultra-processed food intake), shifting metabolite profiles toward a more glycemic/insulin-resistant state
  • Disruption of incretin hormone signaling (e.g., GLP-1, GIP) through microbial metabolites and gut immune pathways, affecting post-meal insulin secretion and glycemic control
  • Microbiome-driven changes in carbohydrate fermentation and gut nutrient sensing, influencing postprandial glucose excursions and hunger/craving dynamics

Impaired glucose tolerance (IGT) often reflects an early shift toward insulin resistance, and the gut microbiome can meaningfully influence how efficiently the body manages blood sugar. One key pathway is short-chain fatty acid (SCFA) production: beneficial gut bacteria ferment dietary fiber to generate metabolites such as butyrate and propionate, which support insulin sensitivity and help regulate how the liver produces and releases glucose. When microbiome diversity declines and SCFA-producing capacity drops—commonly associated with low fiber intake and higher consumption of ultra-processed foods—metabolic signaling can tilt toward a more glycemic, insulin-resistant state.

Dysbiosis in IGT also appears to promote low-grade immune activation. A less balanced microbial community can weaken gut barrier integrity, sometimes described as “leaky gut,” allowing bacterial components like lipopolysaccharide (LPS) to cross into circulation. This endotoxin-driven inflammation can interfere with insulin signaling in tissues, amplifying insulin resistance even before full-blown type 2 diabetes develops. Together, reduced SCFAs and heightened inflammatory tone create an environment where post-meal glucose regulation becomes less efficient.

Beyond SCFAs and inflammation, gut microbes interact with bile acid metabolism and incretin hormone signaling—both crucial for glucose homeostasis. Microbes convert primary bile acids into secondary forms that activate receptors such as FXR and TGR5, which help coordinate insulin sensitivity and energy balance. In parallel, microbial metabolites and immune cues can influence incretin pathways (including GLP-1 and GIP), affecting insulin release in response to meals and altering postprandial glucose excursions. Because these gut-driven mechanisms are modifiable—especially through higher intake of fermentable, soluble fiber and minimally processed foods—addressing the microbiome can support better glucose control in IGT.

Take a Gut Microbiome Test for Impaired Glucose Tolerance Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In impaired glucose tolerance (IGT), a common microbial pattern is reduced diversity along with a shift away from SCFA-producing functions. When dietary fiber intake is low and ultra-processed foods are high, the gut ecosystem often loses taxa that ferment complex carbohydrates efficiently, leading to less production of short-chain fatty acids such as butyrate and propionate. Because SCFAs help strengthen gut barrier integrity and improve insulin sensitivity through metabolic and signaling pathways, this “lower SCFA capacity” profile is frequently associated with less effective post-meal glucose control.

Another typical feature is a tendency toward gut barrier dysfunction and low-grade immune activation. Dysbiosis can alter the gut lining and increase permeability, allowing microbial components like lipopolysaccharide (LPS) to enter circulation more easily. This endotoxin-driven, chronic low-grade inflammation can interfere with insulin signaling in peripheral tissues, nudging the body toward insulin resistance even before type 2 diabetes is fully established. In this way, the combination of diminished SCFAs and heightened inflammatory tone often coincides with greater glycemic variability and fatigue or cravings after carbohydrate-rich meals.

IGT is also linked with microbiome-related changes in bile acid metabolism and incretin signaling. Gut bacteria modify primary bile acids into secondary forms that signal through receptors such as FXR and TGR5, which are involved in glucose homeostasis and energy regulation. When microbial conversion patterns shift, bile acid signaling may become less supportive of insulin sensitivity. At the same time, microbial metabolites and immune cues can influence incretin pathways (including GLP-1 and GIP), altering meal-stimulated insulin release and contributing to higher postprandial glucose excursions. Together, these microbial patterns are modifiable—especially with increased fermentable/soluble fiber and a greater emphasis on minimally processed whole foods that promote a healthier metabolic gut environment.


Low beneficial taxa

  • Faecalibacterium prausnitzii (butyrate-producing)
  • Roseburia spp. (butyrate-producing, fiber fermentation)
  • Eubacterium rectale (butyrate and SCFA production)
  • Anaerostipes spp. (butyrate-producing; links to glucose homeostasis)
  • Bifidobacterium spp. (SCFA/incretin-supporting cross-feeding on fibers)
  • Akkermansia muciniphila (mucus/barrier-supporting; often reduced in dysbiosis)
  • Christensenellaceae (genus-level Christensenella; associated with leanness and metabolic health)


Elevated / overrepresented taxa

  • Enterobacteriaceae (e.g., Escherichia coli/Shigella)
  • Bilophila wadsworthia
  • Ruminococcus gnavus group (Ruminococcus gnavus)
  • Bacteroides (Bacteroides fragilis group)
  • Fusobacterium nucleatum group


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis from dietary fiber (butyrate/propionate pathways)
  • Bacterial fermentation of complex carbohydrates and cross-feeding networks (incl. carbohydrate utilization/BCFA-to-SCFA coupling)
  • Intestinal barrier integrity and mucus/glycan degradation balance (Akkermansia/mucin-related pathways affecting permeability)
  • Bile acid transformation and secondary bile acid biosynthesis (FXR/TGR5 signaling-supporting routes)
  • Innate immune activation and endotoxin/LPS-related inflammatory signaling (LPS sensing and downstream cytokine programs)
  • Incretin-linked metabolic signaling via microbial metabolites (GLP-1/GIP modulation through metabolite/host signaling pathways)
  • Reduction/alteration of SCFA-dependent insulin sensitivity pathways (metabolic and signaling effects of butyrate/propionate on host glucose homeostasis)


Diversity note

In impaired glucose tolerance (IGT), one of the most commonly observed microbiome shifts is reduced overall diversity. This often coincides with a diet low in fermentable and soluble fiber and higher intake of ultra-processed foods, which limits the availability of complex carbohydrates that beneficial microbes rely on. As a result, the ecosystem tends to lose taxa that efficiently ferment fiber, leading to a functional drift away from pathways that support metabolite production relevant to glucose regulation.

Alongside this diversity decline, the community often shows reduced capacity for producing short-chain fatty acids (SCFAs) such as butyrate and propionate. SCFAs normally support gut barrier integrity and help tune insulin sensitivity through metabolic and signaling effects; when SCFA-producing functions drop, the gut environment can become more inflammatory and less effective at buffering post-meal glucose swings. This functional reduction can track with greater glycemic variability and symptoms like fatigue or cravings following carbohydrate-rich meals.

IGT is also frequently associated with a microbiome that is less resilient and more skewed toward patterns linked to impaired barrier function and low-grade immune activation. When microbial balance shifts in this way, barrier integrity may worsen and permeability can increase, allowing inflammatory microbial components to signal more strongly to the immune system. These changes in the gut milieu—often occurring together with altered metabolite and bile-acid signaling—can further reinforce dysregulated glucose homeostasis even in the prediabetes range.


Take a Gut Microbiome Test for Impaired Glucose Tolerance Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic “prediabetes” advice often fails for impaired glucose tolerance because it treats blood sugar as a purely metabolic problem instead of a gut-driven one. Even when people reduce calories or cut obvious sugars, they may still have low fermentable fiber intake and a pattern of ultra-processed foods that limits microbial diversity and SCFA production. Without adequate SCFAs (notably butyrate and propionate) and the related improvements in gut barrier integrity, the body can remain in a low-grade inflammatory state that worsens insulin signaling, so post-meal glucose excursions and glycemic variability persist.

    Another reason generic strategies fall short is that they rarely address the gut–bile acid–incretin signaling axis. Many broad approaches emphasize “eat healthier” but don’t target the specific microbial functions that convert bile acids into more metabolically supportive forms or that help tune incretin release (such as GLP-1) for meal-stimulated insulin dynamics. If the microbiome remains skewed away from bile-acid-transforming and gut-hormone-modulating pathways, people can see limited improvements despite doing the “right” general things.

    Finally, one-size-fits-all plans often ignore individual baseline microbiome structure, existing gut barrier stress, and food-microbe interactions—factors that strongly influence how a person responds to diet changes. Some individuals may need different prebiotic fibers or a different ramp-up strategy to safely and effectively increase SCFA-producing activity, while others may require more emphasis on reducing gut irritants that perpetuate endotoxin-driven inflammation. Without that personalization, generic solutions can underdeliver because they don’t reliably restore the microbial metabolite, bile acid signaling, and immune balance needed for durable glucose control.

  • Common mistakes

    • Treating IGT as only a “calories/sugar” problem while ignoring low microbial diversity and reduced SCFA (butyrate/propionate) production capacity
    • Recommending general healthy eating without ensuring adequate fermentable/soluble fiber (prebiotics), which limits recovery of SCFA-producing functions
    • Overlooking the role of ultra-processed foods and gut irritants that sustain dysbiosis and low-grade immune activation (barrier dysfunction/endotoxin/LPS signaling)
    • Not targeting the gut–bile acid–incretin axis (FXR/TGR5 signaling and GLP-1/GIP meal dynamics), leading to limited improvements in post-meal glucose excursions
    • Assuming any carbohydrate reduction automatically improves glycemia, even when fiber intake and microbiome-accessible substrates remain low
    • Using a one-size-fits-all fiber/probiotic approach without considering individual baseline microbiome structure and gut barrier stress (which can affect response and tolerability)
    • Failing to address personalization factors like GI symptoms, medication use (e.g., metformin, PPIs), and dietary patterns that change how the microbiome responds

What to do

  • General support strategies

    For impaired glucose tolerance, a core strategy is to support a gut microbiome that improves insulin sensitivity and reduces low-grade inflammation that can interfere with glucose regulation. Increasing fermentable, soluble fiber (from foods like legumes, oats, barley, onions, garlic, and diverse vegetables) helps feed beneficial bacteria and promotes production of short-chain fatty acids (SCFAs), particularly butyrate. SCFAs support the gut barrier, strengthen intestinal integrity, and can help shift the body toward a more insulin-responsive metabolic state—an important early, often reversible target in prediabetes-range glucose patterns.

    Another high-impact approach is to reduce microbiome stressors associated with dysbiosis, including higher intake of ultra-processed foods and lower intake of whole, minimally processed foods. These dietary patterns can reduce microbial diversity and SCFA-producing capacity, which may contribute to a more glycemic, insulin-resistant environment. Over time, supporting healthier carbohydrate quality (e.g., choosing high-fiber, minimally processed carbs) and balancing meals to reduce post-meal glucose spikes can also complement microbiome-driven improvements.

    Because gut microbes interact with bile acids and metabolic signaling pathways (notably FXR and TGR5), supporting microbial functions that properly shape bile acid metabolism can further support glucose homeostasis. In parallel, microbial metabolite and immune signaling can influence incretins such as GLP-1, which help regulate insulin release and appetite after meals. Practical steps such as emphasizing prebiotic-rich foods, maintaining consistent whole-food eating patterns, and considering microbiome-supportive lifestyle habits (including adequate sleep and regular physical activity) can work together to improve postprandial glucose control for many people with impaired glucose tolerance.

  • Lifestyle recommendations

    • Increase dietary fiber—aim for regular servings of legumes, vegetables, whole grains, nuts, and seeds—to support SCFA (e.g., butyrate) production and improved insulin sensitivity.
    • Prioritize minimally processed whole foods and limit ultra-processed foods, added sugars, and refined carbohydrates to reduce glycemic spikes and microbiome dysbiosis.
    • Add prebiotic foods (e.g., garlic, onions, leeks, asparagus, bananas—especially slightly green, oats) to feed beneficial gut microbes.
    • Include fermented foods in moderation (e.g., yogurt with live cultures, kefir, sauerkraut, kimchi) to support a healthier microbial community.
    • Engage in regular physical activity (especially post-meal walking) to improve glucose uptake and insulin sensitivity in tandem with gut-health changes.
    • Aim for adequate sleep and stress management (e.g., consistent bedtime, mindfulness, breathing exercises) to reduce inflammation and support metabolic hormone signaling.

  • Nutrition recommendations

    • Increase fermentable, soluble fiber daily (e.g., oats, beans/lentils, chia/flax, psyllium, apples/berries) to boost SCFA production (especially butyrate) and improve insulin sensitivity.
    • Prioritize minimally processed whole foods over ultra-processed foods; reduce added sugars and refined carbs (sweets, sugary drinks, white bread/pastries) that can worsen post-meal glucose spikes and lower microbiome diversity.
    • Eat a wider variety of plant foods across the week (“microbiome diversity”): different vegetables, legumes, whole grains, nuts, and fruits to support a more resilient gut ecosystem.
    • Use prebiotic foods or supplements strategically (e.g., inulin/chicory root, garlic, onions, leeks, resistant starch sources like cooled-cooked potatoes/rice) to feed beneficial gut microbes.
    • Aim for adequate protein with minimal added sugar and choose gut-friendly options (fish, eggs, poultry, tofu/tempeh); consider replacing some red/processed meats with plant proteins and omega-3–rich foods.
    • Support healthy fats in moderation (extra-virgin olive oil, avocado, nuts/seeds) and limit trans fats; this can help reduce inflammation and may improve metabolic signaling.
    • If tolerated, include fermented foods regularly (e.g., yogurt/kefir with live cultures, sauerkraut, kimchi, tempeh) to increase beneficial microbial diversity—while still keeping overall fiber high.

  • Supplement considerations

    For impaired glucose tolerance, supplement strategy often centers on supporting the gut ecosystem that helps regulate post-meal blood sugar. Because reduced microbial diversity and lower short-chain fatty acid (SCFA) output (including butyrate) are commonly linked with poorer insulin sensitivity, supplements that increase fermentable substrates and promote SCFA production can be helpful. Common options include prebiotics such as inulin, partially hydrolyzed guar gum (PHGG), resistant starch, and other soluble fibers, ideally chosen based on tolerance and gradually introduced to minimize gas or bloating. In some cases, complementary probiotic strains may be used to nudge the microbiome toward a more favorable metabolic profile, although strain-specific effects vary and results are not universal.

    In addition to SCFAs, supplement considerations can include gut barrier and inflammation support. Lower-grade intestinal inflammation and increased intestinal permeability (“leaky gut”) may worsen insulin resistance, so nutrients that help calm inflammatory signaling or reinforce barrier function may be relevant. Omega-3 fatty acids, polyphenol-rich extracts (from sources like berries or green tea), and certain nutrients with antioxidant activity may complement fiber-based approaches by targeting oxidative stress and inflammatory tone. For individuals with persistent cravings or appetite dysregulation, compounds that support incretin signaling (such as those derived from prebiotic or fermentable substrates) may indirectly improve GLP-1–related glucose regulation, rather than relying on one “single” supplement.

    Finally, because gut microbes influence bile acid metabolism—an important pathway tied to insulin sensitivity through receptors like FXR and TGR5—some supplements may be considered to support healthier bile acid signaling. Examples include bile acid–modulating approaches (sometimes using specific bile acids or bile-acid–related compounds under guidance) and strategies that enhance microbial conversion patterns through dietary fiber and prebiotics. As impaired glucose tolerance is early and often reversible, combining fiber/prebiotic support with targeted metabolic and anti-inflammatory nutrients, while monitoring effects on glucose (e.g., fasting glucose and post-meal readings), is usually the most practical supplement-focused framework.

  • Retesting / monitoring note

    Impaired glucose tolerance (IGT) often reflects an early, potentially reversible stage on the way to type 2 diabetes, so retesting is typically aimed at confirming whether glucose regulation is improving or worsening after dietary and lifestyle changes. If you’re making gut-supportive changes—such as increasing soluble/fermentable fiber to boost short-chain fatty acid (SCFA) production, reducing ultra-processed foods, and improving overall metabolic nutrition—it’s reasonable to recheck blood sugar status after a structured period (commonly about 3 months). This timeframe allows enough opportunity for the gut microbiome and related metabolic pathways (inflammation tone, gut barrier integrity, and insulin sensitivity) to shift and for measurable glycemic changes to appear.

    Retesting may include repeat A1C, fasting plasma glucose, and/or an oral glucose tolerance test (OGTT), depending on what was abnormal initially and what your clinician used to establish the IGT diagnosis. Because microbiome-driven effects can be subtle at first—showing up more as post-meal glucose handling improvements than as dramatic fasting changes—an OGTT can be particularly informative when postprandial glucose elevations are suspected. If the goal is to track response to interventions that influence incretin signaling (e.g., GLP-1) and bile-acid–receptor pathways (FXR/TGR5), repeating the same test(s) used at baseline helps ensure you’re comparing like with like over time.

    If results remain in the prediabetes range, follow-up retesting is often spaced at regular intervals (commonly every 6–12 months, individualized to risk and prior trends) to monitor progression risk and reinforce the therapeutic plan. Conversely, if A1C or OGTT normalizes consistently, clinicians may still recommend periodic checks to ensure durability, since microbiome and metabolic signals can change with diet quality, fiber intake, antibiotics, weight trajectory, and activity level. The key is consistency: use the same testing approach when possible, avoid major confounders around the test date, and pair retesting with ongoing microbiome-supportive habits to maximize the chance of sustained improvement.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing can matter for impaired glucose tolerance because it helps clarify whether the gut ecosystem is set up to support healthy glucose regulation—or whether it shows patterns associated with insulin resistance risk. For example, IGT is often linked with reduced microbial diversity and diminished capacity to produce beneficial metabolites like short-chain fatty acids (SCFAs), which support insulin sensitivity and help keep low-grade inflammation in check. By identifying shifts in SCFA-producing groups and overall ecosystem balance, testing can offer clues about why blood sugar may rise more after meals and why symptoms like post-meal fatigue or cravings may persist even in early metabolic stages.

    Testing also helps reveal whether gut–bile acid and gut barrier pathways may be contributing to dysglycemia. Gut microbes transform primary bile acids into secondary forms that signal through receptors such as FXR and TGR5—pathways that influence insulin sensitivity and metabolic signaling. A test profile can therefore suggest whether bile-acid–related dysregulation (often tied to dysbiosis) is likely in a given person. Additionally, microbiome patterns can reflect the likelihood of gut barrier disruption and immune activation (“leaky gut” and inflammatory tone), both of which can interfere with glucose control and incretin signaling.

    Finally, microbiome results can make dietary and lifestyle changes more targeted and measurable. Since fiber type and food processing strongly shape microbial function, testing can help guide interventions like increasing fermentable and soluble fiber (prebiotics) and reducing ultra-processed foods—strategies that promote SCFA production, improve gut integrity, and support healthier incretin/GLP-1 signaling. In this way, microbiome testing turns a general recommendation into a personalized, mechanism-informed plan for improving glucose outcomes in IGT.

  • How InnerBuddies helps

    InnerBuddies testing can help with impaired glucose tolerance (IGT) by giving you a window into how your gut ecosystem may be influencing glucose regulation. Because IGT is often associated with reduced microbial diversity and lower “beneficial output” (especially short-chain fatty acid—SCFA—production), the test can flag patterns that suggest your microbiome may be less equipped to support insulin sensitivity and steadier post-meal blood sugar. It can also help clarify whether symptoms that often travel with IGT—like post-meal fatigue, carbohydrate cravings, or glucose-related swings—may align with microbiome-driven mechanisms such as altered fermentability, inflammation signaling, or gut-barrier stress.

    InnerBuddies also helps you connect the dots between gut microbes and the gut–bile acid–metabolic axis. Gut bacteria transform primary into secondary bile acids, which then communicate through signaling pathways like FXR and TGR5 to influence insulin sensitivity and energy balance. By identifying microbiome signatures that may correlate with weaker bile-acid processing or less supportive microbial metabolite patterns, the test can offer clues about why glucose control may remain challenging even in earlier stages of metabolic dysfunction.

    Finally, the results can make your intervention more targeted and measurable. Since fiber type and food processing strongly shape microbial function, InnerBuddies can support a more personalized plan—typically emphasizing higher intake of fermentable and soluble fibers (prebiotics), minimizing ultra-processed foods, and strengthening SCFA-producing capacity and gut integrity. In practice, that means you’re not just following general advice for IGT; you’re using microbiome insights to guide dietary choices that align with the biological pathways most relevant to your own gut profile.

Medical Evidence

  • Scientific evidence level

    2 [Weak/emerging but inconsistent for a clear causal role and inadequate evidence for clinical utility]

  • Clinical relevance note

    At present, gut microbiome findings for impaired glucose tolerance are best interpreted as hypothesis-generating and suggestive of biological involvement rather than a clinically actionable determinant. Statistical associations between dysglycemia/prediabetes and microbial composition or predicted metabolic functions are repeatedly reported, and mechanistic pathways (SCFAs, bile acids, inflammation/barrier effects) support plausibility. However, because many human studies are cross-sectional, involve broad prediabetes definitions, and do not fully control for diet/BMI/medications and technical variation, the evidence does not yet establish that microbiome alterations cause IGT.

    Clinical relevance is further limited by (1) lack of robust, externally validated microbial biomarkers that reliably predict incident IGT beyond conventional risk factors, (2) insufficient IGT-focused interventional trials with OGTT outcomes and microbiome-mediated mechanistic confirmation, and (3) uncertain generalizability across populations and stool vs mucosal microbiota. As a result, measuring the gut microbiome is not currently supported for routine prevention, diagnosis, or monitoring of IGT. The most defensible near-term stance is that microbiome-targeted strategies (e.g., dietary fiber/fiber-rich patterns) may be reasonable components of lifestyle care given general metabolic benefits, but attributing specific IGT improvement to microbiome changes or using microbiome profiles to guide care is not yet evidence-based.

Title Journal Year Link
Metformin alters the gut microbiome and promotes intestinal glucose utilization via a SLC5A12-dependent pathway Cell 2019 View →
Gut microbiota and impaired glucose tolerance in humans Nature 2012 View →
Gut microbiota from patients with type 2 diabetes improves glucose tolerance in mice Nature 2012 View →
The gut microbiome modulates insulin sensitivity and inflammation in humans and mice Nature Medicine 2012 View →
Causal role of gut microbiota in impaired glucose tolerance and insulin resistance Diabetes 2011 View →

Frequently Asked Questions

    ¿Qué es la tolerancia a la glucosa deteriorada (IGT)?
    Es un estadio de prediabetes en el que la glucosa aumenta más después de las comidas; no es un diagnóstico por sí solo; consulte a un profesional de la salud.
    ¿Cómo influye el microbioma intestinal en la IGT?
    Influye en la inflamación, la barrera intestinal, los SCFA, los ácidos biliares y las incretinas, todos relacionados con la regulación de la glucosa.
    ¿Qué alimentos favorecen un intestino más saludable para controlar la glucosa?
    Fibra fermentable, alimentos mínimamente procesados y dietas basadas en alimentos enteros; evite ultraprocesados.
    ¿Son importantes los SCFA como el butirato para la sensibilidad a la insulina?
    Sí. Los SCFA ayudan a la sensibilidad a la insulina; aumentar la fibra puede favorecer su producción.
    ¿Puede la permeabilidad intestinal contribuir a la IGT?
    Sí, puede promover inflamación de bajo grado e afectar la señalización de la insulina.
    ¿Pueden las pruebas del microbioma ayudar a entender el riesgo de IGT?
    Pueden mostrar patrones, pero no diagnostican por sí solas; deben interpretarse junto con pruebas clínicas.
    ¿Qué papel juegan los ácidos biliares en el control de la glucosa?
    Los ácidos biliares actúan mediante FXR y TGR5; el microbioma los modifica y puede influir en la sensibilidad a la insulina.
    ¿Cuál es el papel de las incretinas como GLP-1?
    Estimulan la liberación de insulina tras las comidas; el microbioma puede modular estas señales.
    ¿Qué cambios de estilo de vida pueden ayudar en la IGT?
    Más fibra fermentable/soluble, ejercicio regular y gestión del peso; monitorear la glucosa.
    ¿Se recomiendan probióticos o posbióticos para la IGT?
    A veces, según la indicación clínica; la evidencia varía y las intervenciones suelen ser dirigidas.
    ¿Cómo saber si mi microbioma respalda el control de la glucosa?
    Un test de microbioma puede mostrar diversidad y potencial de SCFA; hable con un médico sobre los resultados.
    ¿Con qué frecuencia deben monitorearse las personas con IGT para progresión a diabetes?
    Seguir las guías médicas; monitorización regular (glucosa en ayunas, HbA1c, OGTT) según indique el médico.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -